Search Results - "Antineoplastic/adverse effects"

INTRAVITREAL METHOTREXATE IN VEMURAFENIB-INDUCED UVEITIS

Authors: Artémise Dugauquier Ahmad Hussein Awada Elie Motulsky et al.

Contributors: Artémise Dugauquier Ahmad Hussein Awada Elie Motulsky et al.

Source: RETINAL Cases & Brief Reports. 18:455-458

Subject Terms: Male, Methotrexate/adverse effects, Antimetabolites, Antineoplastic, Skin Neoplasms, Antineoplastic Agents, Antineoplastic Agents/adverse effects, Sciences bio-médicales et agricoles, Vemurafenib/adverse effects, Middle Aged, 3. Good health, Antimetabolites, Antineoplastic/adverse effects, Uveitis, Methotrexate, Vemurafenib, Skin Neoplasms/drug therapy, Intravitreal Injections, Uveitis/chemically induced, Humans, Melanoma/drug therapy, Female, Melanoma

File Description: 1 full-text file(s): application/vnd.openxmlformats-officedocument.wordprocessingml.document

Access URL: https://pubmed.ncbi.nlm.nih.gov/36977328
https://biblio.vub.ac.be/vubir/intravitreal-methotrexate-in-vemurafenibinduced-uveitis(fb5d477c-19f3-4841-8925-1a317f51f542).html

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Authors: Suzanne I.M. Neppelenbroek Yvonne M. Geurts Berthe M.P. Aleman et al.

Contributors: Suzanne I.M. Neppelenbroek Yvonne M. Geurts Berthe M.P. Aleman et al.

Source: J Clin Oncol
Journal of Clinical Oncology, 42, 16, pp. 1903-1913

Subject Terms: Adult, 0301 basic medicine, Cancer Research, Adolescent, Netherlands/epidemiology, Breast Neoplasms, Antineoplastic/adverse effects, Young Adult, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Cancer Survivors, Antibiotics, Risk Factors, Humans, Netherlands, Antibiotics, Antineoplastic, Breast Neoplasms/epidemiology, Incidence, ORIGINAL REPORTS, Middle Aged, Hodgkin Disease, 3. Good health, Hodgkin Disease/epidemiology, Oncology, Doxorubicin, Radiation Oncology - Radboud University Medical Center, Female, Doxorubicin/adverse effects, Cancer Survivors/statistics & numerical data

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38359378
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/308188
https://doi.org/10.1200/JCO.23.01386
https://research.rug.nl/en/publications/5dcf08df-f8e0-40d2-a52f-3c4c343c6fe4
https://doi.org/10.1200/JCO.23.01386
https://hdl.handle.net/11370/5dcf08df-f8e0-40d2-a52f-3c4c343c6fe4
https://cris.maastrichtuniversity.nl/en/publications/f95456c3-ea4c-41a2-8bfe-137c2b472bdd
https://doi.org/10.1200/JCO.23.01386
https://dspace.library.uu.nl/handle/1874/454214
https://hdl.handle.net/1887/4209245
https://pure.amsterdamumc.nl/en/publications/5919595d-d71e-4fb4-af4d-9ebae4b16023
https://doi.org/10.1200/JCO.23.01386
https://repository.ubn.ru.nl//bitstream/handle/2066/308188/308188.pdf
https://repository.ubn.ru.nl/handle/2066/308188

Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers: The Importance of Long-Term Follow-Up in Curable Cancers

Authors: John Radford

Source: Radford, J 2024, 'Doxorubicin and Breast Cancer Risk : The Importance of Long-Term Follow-Up in Curable Cancers', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 42, no. 16, pp. 1868-1870. https://doi.org/10.1200/JCO.23.02763

Subject Terms: Antibiotics, Antineoplastic, Breast Neoplasms/drug therapy, Antibiotics, Doxorubicin, Humans, Breast Neoplasms, Female, Doxorubicin/adverse effects, Antibiotics, Antineoplastic/adverse effects, Antineoplastic/adverse effects, Follow-Up Studies

Access URL: https://pubmed.ncbi.nlm.nih.gov/38478798

A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment

Authors: Stefan S. Bielack Carole Soussain Christopher P. Fox et al.

Contributors: Stefan S. Bielack Carole Soussain Christopher P. Fox et al.

Source: J Cancer Res Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Journal of Cancer Research and Clinical Oncology, Vol 150, Iss 10, Pp 1-12 (2024)

Subject Terms: Delayed methotrexate elimination, Antimetabolites, Antineoplastic, Consensus, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Decisió de grup, Otros calificadores::Otros calificadores::/uso terapéutico, Leucovorin, Carboxypeptidases, Glucarpidase, Methotrexate pharmacokinetics, Methotrexate toxicity, Review, DISEASES::Neoplasms, Neoplasms, Antimetabòlits - Ús terapèutic, Humans, PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso, Antimetabolites, Antineoplastic/therapeutic use [MeSH], Europe [MeSH], Leucovorin/administration, Leucovorin/therapeutic use [MeSH], Antimetabolites, Antineoplastic/adverse effects [MeSH], Humans [MeSH], Recombinant Proteins/administration, gamma-Glutamyl Hydrolase/therapeutic use [MeSH], Antimetabolites, Antineoplastic/administration, Methotrexate/administration, Neoplasms/drug therapy [MeSH], Methotrexate/adverse effects [MeSH], Methotrexate/therapeutic use [MeSH], Consensus [MeSH], RC254-282, PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Càncer - Tractament, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::antimetabolitos::antimetabolitos antineoplásicos, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, gamma-Glutamyl Hydrolase, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Antimetabolites, Antineoplastic, Recombinant Proteins, Europe, Methotrexate, ENFERMEDADES::neoplasias

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39356310
https://hdl.handle.net/11351/12270
https://doaj.org/article/723e1414c20948f49d0c4df2e2d91a29
https://repository.publisso.de/resource/frl:6499048
https://hdl.handle.net/11585/1007036
https://link.springer.com/article/10.1007/s00432-024-05945-6
https://doi.org/10.1007/s00432-024-05945-6

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

Authors: André B.P. van Kuilenburg Marjolein C.H. Pleunis-van Empel Rick B. Brouwer et al.

Source: JCO Precision Oncology.

Subject Terms: Male, 0301 basic medicine, Antimetabolites, Antineoplastic, Dihydropyrimidine Dehydrogenase Deficiency/genetics, Dihydrouracil Dehydrogenase (NADP)/genetics, Dihydropyrimidine Dehydrogenase Deficiency, Antimetabolites, Capecitabine/adverse effects, Middle Aged, Antineoplastic/adverse effects, 3. Good health, 03 medical and health sciences, Fatal Outcome, 0302 clinical medicine, Humans, Female, Capecitabine, Dihydrouracil Dehydrogenase (NADP)

Access URL: https://pubmed.ncbi.nlm.nih.gov/38709992
https://hdl.handle.net/11370/34a4f97c-1a9c-42f9-8b8b-b30caf7a95a8
https://research.rug.nl/en/publications/34a4f97c-1a9c-42f9-8b8b-b30caf7a95a8
https://doi.org/10.1200/PO.23.00599
https://pure.amsterdamumc.nl/en/publications/a428c03a-6b96-4c44-831e-c97e8edd308d
https://doi.org/10.1200/PO.23.00599

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview

Authors: Niels Herluf Paulsen Fie Vojdeman Stig Ejdrup Andersen et al.

Source: Basic Clin Pharmacol Toxicol
Paulsen, N H, Vojdeman, F, Andersen, S E, Bergmann, T K, Ewertz, M, Plomgaard, P, Hansen, M R, Esbech, P S, Pfeiffer, P, Qvortrup, C & Damkier, P 2022, ' DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview ', Basic and Clinical Pharmacology and Toxicology, vol. 131, no. 5, pp. 325-346 . https://doi.org/10.1111/bcpt.13782

Subject Terms: 0301 basic medicine, Antimetabolites, Antineoplastic, Dihydrouracil Dehydrogenase (NADP)/genetics, Genotype, Antimetabolites, MINI REVIEWS, acute, toxicity, safety evaluation, Fluorouracil/adverse effects, Medical Oncology, cancer chemotherapy, Antineoplastic/adverse effects, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Humans, Prodrugs, Fluorouracil, Uracil, pharmacokinetics, gene expression/regulation, Dihydrouracil Dehydrogenase (NADP), SNPs

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35997509
https://curis.ku.dk/ws/files/323843805/Basic_Clin_Pharma_Tox_2022_Paulsen_DPYD_genotyping_and_dihydropyrimidine_dehydrogenase_DPD_phenotyping_in_clinical.pdf

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury

Authors: Holger Knoth Martin Bornhäuser Christoph Röllig et al.

Source: Cancer Chemother Pharmacol

Subject Terms: Half-dose glucarpidase, Female [MeSH], Aged [MeSH], High-dose methotrexate, Adult [MeSH], Antimetabolites, Antineoplastic/adverse effects [MeSH], Humans [MeSH], Methotrexate plasma concentration, Middle Aged [MeSH], Acute kidney injury, Acute Kidney Injury/drug therapy [MeSH], Recombinant Proteins/administration, Original Article, Recombinant Proteins/therapeutic use [MeSH], Acute Kidney Injury/chemically induced [MeSH], Male [MeSH], gamma-Glutamyl Hydrolase/therapeutic use [MeSH], Antimetabolites, Antineoplastic/blood [MeSH], Acute Kidney Injury/blood [MeSH], gamma-Glutamyl Hydrolase/administration, Methotrexate/blood [MeSH], Methotrexate/adverse effects [MeSH], Thrombocytopenia/chemically induced [MeSH], Folinic acid, Adult, Male, Antimetabolites, Antineoplastic, gamma-Glutamyl Hydrolase, Acute Kidney Injury, Middle Aged, Thrombocytopenia, Recombinant Proteins, 3. Good health, 03 medical and health sciences, Methotrexate, 0302 clinical medicine, Humans, Female, Aged

Access URL: https://link.springer.com/content/pdf/10.1007/s00280-021-04361-8.pdf
https://pubmed.ncbi.nlm.nih.gov/34669022
https://link.springer.com/article/10.1007%2Fs00280-021-04361-8
https://link.springer.com/content/pdf/10.1007/s00280-021-04361-8.pdf
https://inrepo01.inet.dkfz-heidelberg.de/record/177109
https://pubmed.ncbi.nlm.nih.gov/34669022/
https://repository.publisso.de/resource/frl:6447769

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Authors: Wei, Andrew H Döhner, Hartmut Pocock, Christopher et al.

Source: NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Instituto de Investigación Sanitaria La Fe (IIS La Fe)
Wei, A H, Döhner, H, Pocock, C, Montesinos, P, Afanasyev, B, Dombret, H, Ravandi, F, Sayar, H, Jang, J-H, Porkka, K, Selleslag, D, Sandhu, I, Turgut, M, Giai, V, Ofran, Y, Çakar, M K, de Sousa, A B, Rybka, J, Frairia, C, Borin, L, Beltrami, G, Čermák, J, Ossenkoppele, G J, la Torre, I, Skikne, B, Kumar, K, Dong, Q, Beach, C L, the QUAZAR AML-001 Trial Investigators & Roboz, G J 2020, 'Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission', New England Journal of Medicine, vol. 383, no. 26, pp. 2526-2537. https://doi.org/10.1056/NEJMoa2004444

Subject Terms: Male, Antimetabolites, Antineoplastic, Azacitidine / therapeutic use, Administration, Oral, Drug Administration Schedule, Maintenance Chemotherapy, Antimetabolites, Antineoplastic / therapeutic use, 03 medical and health sciences, 0302 clinical medicine, HSAC HEM, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, Leukemia, Myeloid, Acute / mortality, Nausea / chemically induced, Aged, Aged, 80 and over, Azacitidine / administration & dosage, Azacitidine / adverse effects, Remission Induction, Leukemia, Myeloid, Acute / drug therapy, Antimetabolites, Antineoplastic / adverse effects, Nausea, Middle Aged, Survival Analysis, 3. Good health, Leukemia, Myeloid, Acute, Azacitidine, Quality of Life, Female, Antimetabolites, Antineoplastic / administration & dosage, Maintenance Chemotherapy* / adverse effects

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/33369355
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13820
http://sro.sussex.ac.uk/id/eprint/97498/
https://researchportal.helsinki.fi/fi/publications/oral-azacitidine-maintenance-therapy-for-acute-myeloid-leukemia-i
https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2Fd156c034-cf7b-49fc-b645-eadb5b452959
https://pubmed.ncbi.nlm.nih.gov/33369355/
https://www.nejm.org/doi/full/10.1056/NEJMoa2004444
https://www.ncbi.nlm.nih.gov/pubmed/33369355
https://www.nejm.org/doi/10.1056/NEJMoa2004444
https://doi.org/10.1056/NEJMoa2004444
https://research.vumc.nl/en/publications/d156c034-cf7b-49fc-b645-eadb5b452959
https://pure.amsterdamumc.nl/en/publications/fd30956e-1879-4d61-a5aa-9d4442a362b2
https://doi.org/10.1056/NEJMoa2004444
http://hdl.handle.net/10400.17/4710

Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach

Authors: Eduard Schmulenson Linda Krolop Sven Simons et al.

Source: Cancer Chemother Pharmacol

Subject Terms: Adult, Aged, 80 and over, Male, Antimetabolites, Antineoplastic, Middle Aged, Prognosis, Markov Chains, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Female [MeSH], Follow-Up Studies [MeSH], Patient-reported outcomes, Aged, 80 and over [MeSH], Aged [MeSH], Adult [MeSH], Antimetabolites, Antineoplastic/adverse effects [MeSH], Humans [MeSH], Prospective Studies [MeSH], Middle Aged [MeSH], Capecitabine, Hand-Foot Syndrome/etiology [MeSH], Patient Reported Outcome Measures [MeSH], Original Article, Hand–foot syndrome, Male [MeSH], Neoplasms/pathology [MeSH], Markov Chains [MeSH], Neoplasms/drug therapy [MeSH], Prognosis [MeSH], Hand-Foot Syndrome/pathology [MeSH], Markov model, Capecitabine/adverse effects [MeSH], Neoplasms, Humans, Female, Hand-Foot Syndrome, Patient Reported Outcome Measures, Prospective Studies, 10. No inequality, Aged, Follow-Up Studies

Access URL: https://link.springer.com/content/pdf/10.1007/s00280-020-04128-7.pdf
https://pubmed.ncbi.nlm.nih.gov/32852627
https://link.springer.com/article/10.1007/s00280-020-04128-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478943
https://pubmed.ncbi.nlm.nih.gov/32852627/
https://link.springer.com/content/pdf/10.1007/s00280-020-04128-7.pdf
https://repository.publisso.de/resource/frl:6467042

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients

Authors: Mats O. Karlsson Edgar Schömig Usman Arshad et al.

Contributors: Mats O. Karlsson Edgar Schömig Usman Arshad et al.

Source: Cancer Chemother Pharmacol

Subject Terms: Adult, Male, Cancer Research, Antimetabolites, Antineoplastic, Myelosuppression, 5-Fluorouracil, 610 Medicine & health, Toxicology, Models, Biological, Pharmaceutical Sciences, 03 medical and health sciences, 0302 clinical medicine, 2736 Pharmacology (medical), Humans, 1306 Cancer Research, Pharmacology (medical), Pharmacokinetics, Myeloid Cells, Tissue Distribution, Infusions, Intravenous, Aged, Gastrointestinal Neoplasms, Pharmacology, 3005 Toxicology, Aged [MeSH], Myeloid Cells/pathology [MeSH], Models, Biological [MeSH], Original Article, Nonlinear Dynamics [MeSH], Male [MeSH], Pharmacogenetics, Tissue Distribution [MeSH], Fluorouracil/pharmacology [MeSH], Antimetabolites, Antineoplastic/pharmacology [MeSH], Fluorouracil/administration, Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Antimetabolites, Antineoplastic/adverse effects [MeSH], Humans [MeSH], Gastrointestinal Neoplasms/drug therapy [MeSH], Infusions, Intravenous [MeSH], Middle Aged [MeSH], Pharmacodynamics, Myeloid Cells/drug effects [MeSH], Antimetabolites, Antineoplastic/administration, Prognosis [MeSH], Gastrointestinal Neoplasms/pathology [MeSH], Fluorouracil/adverse effects [MeSH], Middle Aged, Farmaceutiska vetenskaper, Prognosis, 3. Good health, 3004 Pharmacology, Oncology, Nonlinear Dynamics, 10199 Clinic for Clinical Pharmacology and Toxicology, 2730 Oncology, Female, Fluorouracil, Follow-Up Studies

File Description: application/pdf; 5FU-Arshad-Jetter-Taubert-Text-final.pdf - application/pdf; Arshad2020_Article_PredictionOfExposure-drivenMye.pdf - application/pdf

Access URL: https://link.springer.com/content/pdf/10.1007/s00280-019-04028-5.pdf
https://pubmed.ncbi.nlm.nih.gov/32152679
https://europepmc.org/article/PMC/PMC7125253
http://uu.diva-portal.org/smash/record.jsf?pid=diva2:1433122
https://link.springer.com/article/10.1007/s00280-019-04028-5
http://www.ncbi.nlm.nih.gov/pubmed/32152679
http://www.diva-portal.org/smash/record.jsf?pid=diva2:1433122
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125253
https://repository.publisso.de/resource/frl:6467028
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-410140

Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity

Authors: Mukhopadhyay, P. Batkai, S. Rajesh, M. et al.

Subject Terms: Animals Antibiotics, Antineoplastic/*adverse effects Apoptosis/drug effects Cell Line DNA Fragmentation/drug effects Doxorubicin/*adverse effects Endocannabinoids/metabolism Heart Failure, Congestive/*chemically induced/prevention & control Male Mice Mice, Inbred C57BL Morpholines/*pharmacology/therapeutic use Myocardium/metabolism Myocytes, Cardiac/drug effects Piperidines/*pharmacology/therapeutic use Pyrazoles/*pharmacology/therapeutic use Receptor, Cannabinoid, CB1/agonists/*antagonists & inhibitors/drug effects Receptor, CB2/agonists/antagonists & inhibitors/drug effects

File Description: application/pdf

Relation: Journal of the American College of Cardiology; https://iris.unil.ch/handle/iris/88753; serval:BIB_1F70BF7CAFB5; 000248696400008

Availability: https://iris.unil.ch/handle/iris/88753
https://doi.org/10.1016/j.jacc.2007.03.057

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Authors: Dupuis, J. Bachy, E. Morschhauser, F. et al.

Subject Terms: Humans, Male, Female, Aged, Middle Aged, Azacitidine/therapeutic use, Azacitidine/adverse effects, Azacitidine/administration & dosage, Administration, Oral, Bendamustine Hydrochloride/therapeutic use, Bendamustine Hydrochloride/administration & dosage, Bendamustine Hydrochloride/adverse effects, Gemcitabine, Lymphoma, Follicular/drug therapy, Follicular/mortality, Deoxycytidine/analogs & derivatives, Deoxycytidine/therapeutic use, Deoxycytidine/administration & dosage, Deoxycytidine/adverse effects, Depsipeptides/therapeutic use, Depsipeptides/adverse effects, Depsipeptides/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antimetabolites, Antineoplastic/therapeutic use, Antineoplastic/adverse effects, Antineoplastic/administration & dosage

Relation: The Lancet Haematology; https://iris.unil.ch/handle/iris/219231; serval:BIB_90411DAD960E; 001302195200001

Availability: https://iris.unil.ch/handle/iris/219231
https://doi.org/10.1016/S2352-3026(24)00102-9

Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix.

Authors: Delaloye, J.F. Leyvraz, S. Outcha Adjahoto, E. et al.

Subject Terms: Adult, Aged, Antibiotics, Antineoplastic/administration & dosage, Antineoplastic/adverse effects, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/adverse effects, Antineoplastic Agents, Phytogenic/administration & dosage, Phytogenic/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bone Marrow/drug effects, Carcinoma/drug therapy, Cisplatin/administration & dosage, Cisplatin/adverse effects, Disease Progression, Female, Humans, Middle Aged, Mitomycins/administration & dosage, Mitomycins/adverse effects, Neoplasm Recurrence, Local/drug therapy, Remission Induction, Salvage Therapy, Survival Rate, Uterine Cervical Neoplasms/drug therapy, Vindesine/administration & dosage, Vindesine/adverse effects

Relation: American journal of clinical oncology; https://iris.unil.ch/handle/iris/215599; serval:BIB_9EFF64AFF43B; A1996UC42300024; 8610651

Availability: https://iris.unil.ch/handle/iris/215599
https://doi.org/10.1097/00000421-199604000-00024

Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).

Authors: Hirano, H. Kataoka, K. Yamaguchi, T. et al.

Subject Terms: Humans, Colorectal Neoplasms/drug therapy, Colorectal Neoplasms/mortality, Colorectal Neoplasms/pathology, Male, Female, Chemotherapy, Adjuvant/adverse effects, Aged, Sex Factors, Middle Aged, Randomized Controlled Trials as Topic, Neoplasm Staging, Japan/epidemiology, Fluorouracil/adverse effects, Fluorouracil/therapeutic use, Fluorouracil/administration & dosage, Antimetabolites, Antineoplastic/adverse effects, Antineoplastic/therapeutic use, East Asian People, Adjuvant chemotherapy, Colorectal cancer, Fluoropyrimidine, Sex difference

Relation: European Journal of Cancer; https://iris.unil.ch/handle/iris/133490; serval:BIB_94F8DF7BF59E; 001364298000001

Availability: https://iris.unil.ch/handle/iris/133490
https://doi.org/10.1016/j.ejca.2024.115139

Polyethylene Glycol Drug-Eluting Embolic Microspheres Loaded with Doxorubicin for the Treatment of Hepatocellular Carcinoma: Feasibility, Safety, and Pharmacokinetic Study.

Authors: Malagari, K. Denys, A. Burrel, M. et al.

Subject Terms: Antibiotics, Antineoplastic/adverse effects, Carcinoma, Hepatocellular/diagnostic imaging, Hepatocellular/drug therapy, Hepatocellular/pathology, Chemoembolization, Therapeutic/adverse effects, Doxorubicin/adverse effects, Feasibility Studies, Female, Humans, Liver Neoplasms/diagnostic imaging, Liver Neoplasms/drug therapy, Liver Neoplasms/pathology, Male, Microspheres, Polyethylene Glycols/adverse effects, Treatment Outcome

Relation: Journal of Vascular and Interventional Radiology; https://iris.unil.ch/handle/iris/105807; serval:BIB_4BB70DC65E01; 000833350400006

Availability: https://iris.unil.ch/handle/iris/105807
https://doi.org/10.1016/j.jvir.2021.11.019

Intermediate-Dose Cytarabine as Postinduction AML Therapy

Authors: Hunault-Berger, Mathilde Pautas, Cécile Bertoli, Sarah et al.

Contributors: Hunault-Berger, Mathilde Pautas, Cécile Bertoli, Sarah et al.

Source: ISSN: 2766-5526 ; NEJM Evidence ; https://hal.science/hal-05162195 ; NEJM Evidence, 2025, 4 (7), pp.EVIDoa2400326. ⟨10.1056/evidoa2400326⟩.

Subject Terms: Cytarabine, Medicine, Oncology, Internal medicine, Chemotherapy, MESH: Adolescent, MESH: Adult, MESH: Humans, MESH: Leukemia, Myeloid, Acute* / drug therapy, Acute* / mortality, Acute* / therapy, MESH: Male, MESH: Middle Aged, MESH: Remission Induction, MESH: Treatment Outcome, MESH: Young Adult, MESH: Antimetabolites, Antineoplastic* / administration & dosage, Antineoplastic* / adverse effects, Antineoplastic* / therapeutic use, MESH: Cytarabine* / administration & dosage, MESH: Cytarabine* / adverse effects, MESH: Cytarabine* / therapeutic use, MESH: Female, MESH: Hematopoietic Stem Cell Transplantation, [SDV]Life Sciences [q-bio]

Relation: info:eu-repo/semantics/altIdentifier/pmid/40552969; PUBMED: 40552969

Availability: https://hal.science/hal-05162195
https://doi.org/10.1056/evidoa2400326

Long‐term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial: Insight from a randomized clinical trial

Authors: Banke, Ann Fosbøl, Emil L. Møller, Jacob E. et al.

Source: Banke, A, Fosbøl, E L, Møller, J E, Gislason, G H, Andersen, M, Bernsdorf, M, Jensen, M B, Schou, M & Ejlertsen, B 2018, ' Long-term effect of epirubicin on incidence of heart failure in women with breast cancer : Insight from a randomized clinical trial ', European Journal of Heart Failure, vol. 20, no. 10, pp. 1447-1453 . https://doi.org/10.1002/ejhf.1168
Banke, A, Fosbøl, E L, Møller, J E, Gislason, G H, Andersen, M, Bernsdorf, M, Jensen, M-B, Schou, M & Ejlertsen, B 2018, 'Long-term effect of epirubicin on incidence of heart failure in women with breast cancer : insight from a randomized clinical trial', European Journal of Heart Failure, vol. 20, no. 10, pp. 1447-1453. https://doi.org/10.1002/ejhf.1168

Subject Terms: Adult, Denmark, Breast Neoplasms, Anthracycline, Disease-Free Survival, Antineoplastic/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Antibiotics, Risk Factors, Humans, Long-term follow-up, Heart Failure/chemically induced, Aged, Epirubicin, Retrospective Studies, Heart Failure, Survival Rate/trends, Antibiotics, Antineoplastic, Epirubicin/adverse effects, Incidence, Breast Neoplasms/diagnosis, Middle Aged, Cardiotoxicity, Chronic heart failure, Denmark/epidemiology, 3. Good health, Survival Rate, Cardio-oncology, 13. Climate action, Female, Antibiotics, Antineoplastic/adverse effects, Follow-Up Studies, Forecasting

Access URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.1168
https://pubmed.ncbi.nlm.nih.gov/29493047
https://pubmed.ncbi.nlm.nih.gov/29493047/
https://www.ncbi.nlm.nih.gov/pubmed/29493047
https://core.ac.uk/display/159412271
https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1168
https://portal.findresearcher.sdu.dk/da/publications/c9dee511-62e0-4f6a-8184-015761f100a1
https://portal.findresearcher.sdu.dk/da/publications/c9dee511-62e0-4f6a-8184-015761f100a1
https://doi.org/10.1002/ejhf.1168
https://pure.au.dk/portal/en/publications/eec1f191-86bf-42dd-b567-a66c52b517df
http://www.scopus.com/inward/record.url?scp=85042594109&partnerID=8YFLogxK
https://doi.org/10.1002/ejhf.1168

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases: uracil plasma ratio in patients with colorectal liver metastases

Authors: Maarten J. Deenen Bart A. W. Jacobs Niels de Vries et al.

Contributors: Maarten J. Deenen Bart A. W. Jacobs Niels de Vries et al.

Source: European Journal of Clinical Pharmacology. 74:737-744

Subject Terms: Male, 0301 basic medicine, Antimetabolites, Antineoplastic, Organoplatinum Compounds, Antimetabolites, Clinical Trial, Phase III, Observational Study, Bevacizumab/adverse effects, Antineoplastic/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Taverne, Antineoplastic Combined Chemotherapy Protocols, Journal Article, 80 and over, Humans, Pharmacology (medical), Organoplatinum Compounds/adverse effects, Uracil, Colorectal Neoplasms/blood, Capecitabine, Aged, Pharmacology, Aged, 80 and over, Uracil/analogs & derivatives, Liver/surgery, Liver Neoplasms/blood, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Liver Neoplasms, Capecitabine/adverse effects, Middle Aged, Antimetabolites, Antineoplastic/adverse effects, 3. Good health, Multicenter Study, Bevacizumab, Oxaliplatin, Liver, Female, Colorectal Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/29430582
https://europepmc.org/abstract/MED/29430582
https://core.ac.uk/display/160115079
https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F376779
http://dspace.library.uu.nl/handle/1874/366129
https://pubmed.ncbi.nlm.nih.gov/29430582/
https://link.springer.com/article/10.1007/s00228-018-2426-4
https://dspace.library.uu.nl/handle/1874/366129
https://dspace.library.uu.nl/handle/1874/376779

Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model

Authors: Kiara Wanner Nicole Williams Imogen A. Ball et al.

Contributors: Kiara Wanner Nicole Williams Imogen A. Ball et al.

Source: Chemotherapy. 63:284-292

Subject Terms: Diarrhea, 0301 basic medicine, Methotrexate/adverse effects, Antimetabolites, Antineoplastic, Antimetabolites, Transplantation, Heterologous, diarrhea, Adverse drug reactions, Matrix Metalloproteinase Inhibitors, methotrexate, Antineoplastic/adverse effects, Cell Line, AZD3342, Random Allocation, 03 medical and health sciences, breast cancer, 0302 clinical medicine, Organic Chemicals/adverse effects, Cell Line, Tumor, Neoplasms, Animals, Humans, gastrointestinal toxicity, Intestinal Mucosa, Organic Chemicals, intervention, Matrix Metalloproteinases/chemistry, adverse drug reactions, Transplantation, Heterologous, Tumor, Intestinal Mucosa/pathology, rat model, Matrix Metalloproteinase Inhibitors/adverse effects, matrix metalloproteinases, Matrix Metalloproteinases, Neoplasms/drug therapy, Rats, 3. Good health, mucositis, Methotrexate, Diarrhea/etiology, Female

File Description: application/pdf

Access URL: https://www.karger.com/Article/Pdf/495470
https://pubmed.ncbi.nlm.nih.gov/30731451
https://europepmc.org/articles/PMC6425820
https://pubmed.ncbi.nlm.nih.gov/30731451/
https://digital.library.adelaide.edu.au/dspace/handle/2440/119238
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425820/
https://pure.rug.nl/ws/files/79452813/Selective_MMP_Inhibition_Using_AZD3342_to_Reduce_Gastrointestinal_Toxicity_and_Enhance_Chemoefficacy_in_a_Rat_Model.pdf
https://research.rug.nl/en/publications/selective-mmp-inhibition-using-azd3342-to-reduce-gastrointestinal
https://hdl.handle.net/11541.2/136081

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

Authors: Stew Kroll Lee D. Cranmer Scott H. Okuno et al.

Source: The Lancet Oncology. 18:1089-1103

Subject Terms: Soft Tissue Neoplasms/drug therapy, Male, Sarcoma/drug therapy, Phosphoramide Mustards/administration & dosage, Soft Tissue Neoplasms, Stomatitis/chemically induced, Disease-Free Survival, Antineoplastic/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Antibiotics, Drug Eruptions/etiology, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Stomatitis, Antibiotics, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Doxorubicin/administration & dosage, Sarcoma, Exanthema, Middle Aged, 16. Peace & justice, Hematologic Diseases, 3. Good health, Survival Rate, Hematologic Diseases/chemically induced, Doxorubicin, Nitroimidazoles, Nitroimidazoles/administration & dosage, Female, Phosphoramide Mustards, Drug Eruptions, Exanthema/chemically induced

Access URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771354
https://pubmed.ncbi.nlm.nih.gov/28651927
https://pubmed.ncbi.nlm.nih.gov/28651927/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771354
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30381-9/fulltext
https://mayoclinic.pure.elsevier.com/en/publications/doxorubicin-plus-evofosfamide-versus-doxorubicin-alone-in-locally
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30381-9/fulltext
https://arizona.pure.elsevier.com/en/publications/doxorubicin-plus-evofosfamide-versus-doxorubicin-alone-in-locally